[1]王海燕,张剑平,王雨生.当前监测新生血管性年龄相关性黄斑变性患者对侧眼的观念和方法——专家共识解读[J].眼科新进展,2022,42(1):001-5.[doi:10.13389/j.cnki.rao.2022.0001]
　WANG Haiyan,ZHANG Jianping,WANG Yusheng.Interpretation of expert consensus on “current concepts and methods for monitoring the fellow eye of patients with neovascular age-related macular degeneration”[J].Recent Advances in Ophthalmology,2022,42(1):001-5.[doi:10.13389/j.cnki.rao.2022.0001]
点击复制

当前监测新生血管性年龄相关性黄斑变性患者对侧眼的观念和方法——专家共识解读/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年1期
页码:
001-5
栏目:
述评
出版日期:
2022-01-05

文章信息/Info

Title:
Interpretation of expert consensus on “current concepts and methods for monitoring the fellow eye of patients with neovascular age-related macular degeneration”
作者:
王海燕; 张剑平; 王雨生
710004　陕西省西安市，西安市人民医院（西安市第四医院），陕西省眼科医院（王海燕，张剑平）；710032　陕西省西安市，空军军医大学西京医院眼科，全军眼科研究所（王雨生）
Author(s):
WANG Haiyan1; ZHANG Jianping1; WANG Yusheng2
1.Xi’an People’s Hospital (Xi’an Fourth Hospital),Shaanxi Eye Hospital,Xi’an 710004,Shaanxi Province,China
2.Department of Ophthalmology,Eye Institute of Chinese PLA,Xijing Hospital,Fourth Military Medical University,Xi’an 710032,Shaanxi Province,China
关键词:
年龄相关性黄斑变性; 脉络膜新生血管; 眼底影像检查; 监测方法
Keywords:
age-related macular degeneration;  choroidal neovascularization;  fundus imaging;  monitoring methods
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2022.0001
文献标志码:
A
摘要:
新生血管性年龄相关性黄斑变性（nAMD）常双眼先后发病，一眼发病后如何保持对侧眼有用的视功能与患者的生活质量密切相关。因此，监测nAMD患者对侧眼的发病情况就尤为重要。近年，远景学院（Vision Academy）的眼底病专家发起了“当前监测nAMD患者对侧眼的观念和方法”专家共识，该共识提出早期发现nAMD患者对侧眼脉络膜新生血管的重要性，并对目前的监测方法进行了分析，推荐每3～4个月进行一次对侧眼的检查，并鼓励利用家用技术和设备进行监测，以期早期发现、及时治疗。
Abstract:
Neovascular age-related macular degeneration (nAMD) is commonly considered a bilateral disease even without simultaneous onset in both eyes. Following the presence of nAMD in one eye, maintaining the visual function of the fellow eye correlates closely to the patient’s quality of life. Hence, it is particularly important to monitor and detect nAMD in the fellow, better-seeing eye of nAMD patients. Sponsored by the retinal expert panel from the Vision Academy, the consensus on “current concepts and methods for monitoring the fellow eye of patients with neovascular age-related macular degeneration” proposed the significance of early detection of choroidal neovascularization (CNV) in the fellow eye of nAMD patients and meanwhile assessed the currently available monitoring methods. It is recommended to examine the fellow eye every 3-4 months from the time of CNV detected in the first eye. Monitoring the fellow eye with home-based technology and equipment is also encouraged so that CNV can be detected and treated as soon as possible.

参考文献/References:

［1］　WONG T Y,LANZETTA P,BANDELLO F,ELDEM B,NAVARRO R,LVESTAM-ADRIAN M,et al.Current concepts and modalities for monitoring the fellow eye in neovascular age-related macular degeneration:an expert panel consensus［J］.Retina,2020,40(4):599-611.
［2］　CHEW J K,ZHU M,BROADHEAD G K,LUO K,HONG T,CHANG A A.Bilateral neovascular age-related macular degeneration:comparisons between first and second eyes［J］.Ophthalmologica,2017,238(1/2):23-30.
［3］　WOLF S,BANDELLO F,LOEWENSTEIN A,SLAKTER J,KATZ T,SOWADE O,et al.Baseline characteristics of the fellow eye in patients with neovascular age-related macular degeneration:Post Hoc analysis of the VIEW studies［J］.Ophthalmologica,2016,236(2):95-99.
［4］　WONG T Y,CHAKRAVARTHY U,KLEIN R,MITCHELL P,ZLATEVA G,BUGGAGE R,et al.The natural history and prognosis of neovascular age-related macular degeneration:a systematic review of the literature and meta-analysis［J］.Ophthalmology,2008,115(1):116-126.
［5］　FASLER K,FU D J,MORAES G,WAGNER S,GOKHALE E,KORTUEM K,et al.Moorfields AMD database report 2:fellow eye involvement with neovascular age-related macular degeneration［J］.Br J Ophthalmol,2020,104(5):684-690.
［6］　LEE J,CHOI S,LEE C S,KIM M,KIM S S,KOH H J,et al.Neovascularization in fellow eye of unilateral neovascular age-related macular degeneration according to different drusen types［J］.Am J Ophthalmol,2019,208(12):103-110.
［7］　PARIKH R,AVERY R L,SAROJ N,THOMPSON D,FREUND K B.Incidence of new choroidal neovascularization in fellow eyes of patients with age-related macular degeneration treated with intravitreal aflibercept or ranibizumab［J］.JAMA Ophthalmol,2019,137(8):914-920.
［8］　MAGUIRE M G,DANIEL E,SHAH A R,GRUNWALD J E,HAGSTROM S,AVERY R L,et al.Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials［J］.Ophthalmology,2013,120(10):2035-2041.
［9］　PAULUS Y M,JEFFERYS J L,HAWKINS B S,SCOTT A W.Visual function quality of life measure changes upon conversion to neovascular age-related macular degeneration in second eyes［J］.Qual Life Res,2017,26(8):2139-2151.
［10］　YING G S,HUANG J,MAGUIRE M G,JAFFE G J,GRUNWALD J E,TOTH C,et al.Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration［J］.Ophthalmology,2013,120(1):122-129.
［11］　LEE A Y,LEE C S,BUTT T,XING W,JOHNSTON R L,CHAKRAVARTHY U,et al.UK AMD EMR users group report V:benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12［J］.Br J Ophthalmol,2015,99(8):1045-1050.
［12］　KAISER P K,SINGER M,TOLENTINO M,VITTI R,ERICKSON K,SAROJ N,et al.Long-term safety and visual outcome of intravitreal aflibercept in neovascular age-related macular degeneration:VIEW 1 extension study［J］.Ophthalmol Retina,2017,1(4):304-313.
［13］　JOACHIM N,COLIJN J M,KIFLEY A,LEE K E,BUITENDIJK G,KLEIN B,et al.Five-year progression of unilateral age-related macular degeneration to bilateral involvement:the three continent AMD consortium report［J］.Br J Ophthalmol,2017,101(9):1185-1192.
［14］　MANN S S,RUTISHAUSER-ARNOLD Y,PETO T,JENKINS S A,LEUNG I,XING W,et al.The symmetry of phenotype between eyes of patients with early and late bilateral age-related macular degeneration (AMD)［J］.Graefes Arch Clin Exp Ophthalmol,2011,249(2):209-214.
［15］　KEANE P,DE SALVO G,SIM D A,GOVERDHAN S,AGRAWAL R,TUFAIL A.Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration［J］.Clin Ophthalmol,2015,9:353-366.
［16］　LIU T Y,SHAH A R,DEL PRIORE L V.Progression of lesion size in untreated eyes with exudative age-related macular degeneration:a meta-analysis using Lineweaver-Burk plots［J］.JAMA Ophthalmol,2013,131(3):335-340.
［17］　SCHWARTZ R,LOEWENSTEIN A.Early detection of age related macular degeneration:current status［J］.Int J Retina Vitreous,2015,1:20.
［18］　BRESSLER N M.Early detection and treatment of neovascular age-related macular degeneration［J］.J Am Board Fam Pract,2002,15(2):142-152.
［19］　VARANO M,ETER N,WINYARD S,WITTRUP-JENSEN K,NAVARRO R,HERAGHTY J.Current barriers to treatment for wet age-related macular degeneration (wAMD):findings from the wAMD patient and caregiver survey［J］.Clin Ophthalmol,2015,9:2243-2250.
［20］　TREVINO R.Recent progress in macular function self-assessment［J］.Ophthalmic Physiol Opt,2008,28(3):183-192.
［21］　WANG Y Z,HE Y G,MITZEL G,ZHANG S,BARTLETT M.Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy［J］.Invest Ophthalmol Vis Sci,2013,54(8):5497-5505.
［22］　KIM T N,MYERS F,REBER C,LOURY P J,LOUMOU P,WEBSTER D,et al.A smartphone-based tool for rapid,portable,and automated wide-field retinal imaging［J］.Transl Vis Sci Technol,2018,7(5):21.
［23］　BRADY C J,EGHRARI A O,LABRIQUE A B.Smart phone-based visual acuity measurement for screening and clinical assessment［J］.JAMA,2015,314(24):2682-2683.
［24］　TOFIGH S,SHORTRIDGE E,ELKEEB A,GODLEY B F.Effectiveness of a smartphone application for testing near visual acuity［J］.Eye (Lond),2015,29(11):1464-1468.
［25］　DORR M,LESMES L A,LU Z L,BEX P J.Rapid and reliable assessment of the contrast sensitivity function on an iPad［J］.Invest Ophthalmol Vis Sci,2013,54(12):7266-7273.
［26］　HO C,WU Z,TURPIN A,LAWSON D J,LUU C D,MCKENDRICK A M,et al.A Tablet-based retinal function test in neovascular age-related macular degeneration eyes and at-risk fellow eye［J］.Transl Vis Sci Technol,2018,7(2):2.
［27］　WU Z,GUYMER R H,JUNG C J,GOH J K,AYTON L N,LUU C D,et al.Measurement of retinal sensitivity on tablet devices in age-related macular degeneration［J］.Transl Vis Sci Technol,2015,4(3):13.
［28］　MAESA J M,BAOS-LVAREZ E,ROSARIO-LOZANO M P,BLASCO-AMARO J A.Diagnostic accuracy of optical coherence tomography angiography in the detection of neovasculature in age-related macular degeneration:a meta-analysis［J］.Acta Ophthalmol,2021.［Online ahead of print］.doi:10.1111/aos.14979.
［29］　QUERQUES G,SROUR M,MASSAMBA N,GEORGES A,BEN MOUSSA N,RAFAELI O,et al.Functional characterization and multimodal imaging of treatment-naive “quiescent” choroidal neovascularization［J］.Invest Ophthalmol Vis Sci,2013,54(10):6886-6892.
［30］　SOLECKI L,LOGANADANE P,GAUTHIER A S,SIMONIN M,PUYRAVEAU M,DELBOSC B,et al.Predictive factors for exudation of quiescent choroidal neovessels detected by OCT angiography in the fellow eyes of eyes treated for a neovascular age-related macular degeneration［J］.Eye (Lond),2021,35(2):644-650.
［31］　YANAGI Y,MOHLA A,LEE S Y,MATHUR R,CHAN C M,YEO I,et al.Incidence of fellow eye involvement in patients with unilateral exudative age-related macular degeneration［J］.JAMA Ophthalmol,2018,136(8):905-911.
［32］　CARNEVALI A,SACCONI R,QUERQUES L,MARCHESE A,CAPUANO V,RABIOLO A,et al.Natural history of treatment-nave quiescent choroidal neovascularization in age-related macular degeneration using OCT angiography［J］.Ophthalmol Retina,2018,2(9):922-930.
［33］　FUKUSHIMA A,MARUKO I,CHUJO K,HASEGAWA T,ARAKAWA H,IIDA T.Characteristics of treatment-nave quiescent choroidal neovascularization detected by optical coherence tomography angiography in patients with age-related macular degeneration［J］.Graefes Arch Clin Exp Ophthalmol,2021,259(9):2671-2677.
［34］　BAILEY S T,THAWARE O,WANG J,HAGAG A M,ZHANG X,FLAXEL C J,et al.Detection of nonexudative choroidal neovascularization and progression to exudative choroidal neovascularization using OCT angiography［J］.Ophthalmol Retina,2019,3(8):629-636.
［35］　AL-SHEIKH M,IAFE N A,PHASUKKIJWATANA N,SADDA S R,SARRAF D.Biomarkers of neovascular activity in age-related macular degeneration using optical coherence tomography angiography［J］.Retina,2018,38(2):220-230.
［36］　NASSISI M,LEI J,ABDELFATTAH N S,KARAMAT A,BALASUBRAMANIAN S,FAN W,et al.OCT risk factors for development of late age-related macular degeneration in the fellow eyes of patients enrolled in the harbor study［J］.Ophthalmology,2019,126(12):1667-1674.
［37］　FORTE R,COSCAS F,SERRA R,CABRAL D,COLANTUONO D,SOUIED E H.Long-term follow-up of quiescent choroidal neovascularisation associated with age-related macular degeneration or pachychoroid disease［J］.Br J Ophthalmol,2020,104(8):1057-1063.
［38］　SERRA R,COSCAS F,BOULET J F,CABRAL D,LUPIDI M,COSCAS G J,et al.Predictive activation biomarkers of treatment-naive asymptomatic choroidal neovascularization in age-related macular degeneration［J］.Retina,2020,40(7):1224-1233.

相似文献/References:

[1]范姜砾 王雨生 张鹏.湿性年龄相关性黄斑变性患者血浆中相关抗氧化酶水平测定[J].眼科新进展,2012,32(5):000.
[2]王毅 李罗翔 李娟 曾庆华.ApoE基因缺失小鼠视网膜及Bruch膜组织形态观察[J].眼科新进展,2013,33(1):000.
[3]徐新荣 仲路 黄冰林 魏源华 周欣 王玲 王富强.年龄相关性黄斑变性血浆蛋白质组学初步研究[J].眼科新进展,2013,33(2):000.
[4]王毅 李罗翔 李进辉 李娟 曾庆华.血脂异常ApoE基因缺失小鼠视网膜色素上皮细胞胞浆内黑色素和脂褐素的改变[J].眼科新进展,2013,33(7):000.
[5]许瑶 曾骏文.近视眼药物治疗研究进展[J].眼科新进展,2013,33(7):000.
[6]许琴 黄亮 林素香 郑水华 肖煜晨 王雅丽.激光诱导小鼠脉络膜新生血管中膜攻击物与血管生长因子的表达[J].眼科新进展,2013,33(8):000.
[7]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[8]詹文捷 梁丽娜 唐由之.骨髓来源细胞参与脉络膜新生血管形成的研究进展[J].眼科新进展,2012,32(1):000.
[9]陈丽娟 苗林.重组人血管内皮抑素对脉络膜新生血管的抑制作用[J].眼科新进展,2012,32(10):000.
[10]金昱 石安娜 刘维锋 石浔 王永波.频域OCT在光动力疗法治疗病理性近视脉络膜新生血管中的应用[J].眼科新进展,2012,32(10):000.
[11]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[12]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[13]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[14]魏菁,黄厚斌. 吲哚青绿介导的光栓塞治疗黄斑中心凹下脉络膜新生血管[J].眼科新进展,2014,34(9):842.[doi:10.13389/j.cnki.rao.2014.0232]
[15]于靖,刘晴雨,吴岩.阿司匹林是年龄相关性黄斑变性的危险因素[J].眼科新进展,2014,34(10):901.[doi:10.13389/j.cnki.rao.2014.0249]
[16]朱磊,田晓燕,刘涛.玻璃体内注射康柏西普治疗湿性年龄相关性黄斑变性的临床观察[J].眼科新进展,2017,37(5):473.[doi:10.13389/j.cnki.rao.2017.0120]
　ZHU Lei,TIAN Xiao-Yan,LIU Tao.Intravitreal injection of conbercept for wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2017,37(1):473.[doi:10.13389/j.cnki.rao.2017.0120]
[17]卢悦,蔡玲,朱晨,等.人参皂苷RG3对脉络膜新生血管的抑制作用[J].眼科新进展,2017,37(10):922.[doi:10.13389/j.cnki.rao.2017.0234]
　LU Yue,CAI Ling,ZHU Chen,et al.Inhibitory effect of ginsenoside RG3 on choroidal neovascularization[J].Recent Advances in Ophthalmology,2017,37(1):922.[doi:10.13389/j.cnki.rao.2017.0234]
[18]邵毅,周琼.年龄相关性黄斑变性诊断与治疗规范——2018年英国专家共识解读[J].眼科新进展,2019,39(11):1001.[doi:10.13389/j.cnki.rao.2019.0229]
　SHAO Yi,ZHOU Qiong.Diagnosis and treatment of age-related macular degeneration:An interpretation of British National Institute for Health and Care Excellence (NICE) in 2018[J].Recent Advances in Ophthalmology,2019,39(1):1001.[doi:10.13389/j.cnki.rao.2019.0229]
[19]胡伟男,蔡文婷,邹爱琪,等.精氨酸-甘氨酸-天冬氨酸修饰的星型高分子负载雷珠单抗对脉络膜新生血管靶向治疗作用[J].眼科新进展,2021,41(2):130.[doi:10.13389/j.cnki.rao.2021.0027]
　HU Weinan,CAI Wenting,ZOU Aiqi,et al.Targeted therapy effect of arginine-glycine-aspartate modified star polymer loaded ranibizumab on choroidal neovascularization[J].Recent Advances in Ophthalmology,2021,41(1):130.[doi:10.13389/j.cnki.rao.2021.0027]
[20]付燕,张月玲,王丽英,等.湿性年龄相关性黄斑变性患者抗VEGF治疗无效的因素分析和视功能预后[J].眼科新进展,2021,41(3):254.[doi:10.13389/j.cnki.rao.2021.0053]
　FU Yan,ZHANG Yueling,WANG Liying,et al.Factors and outcomes associated with failure to anti-VEGF treatment in patients with wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2021,41(1):254.[doi:10.13389/j.cnki.rao.2021.0053]

备注/Memo

备注/Memo:
国家自然科学基金资助项目(编号：81770936)；陕西省重点研发计划项目（编号： 2020SF-26）; 西安市科技计划项目［编号： 20YXYJ0008（3）］；西安市人民医院(西安市第四医院）孵化基金（编号：ZD-5)
更新日期/Last Update: 2022-01-05